Jack Allen

Stock Analyst at Baird

(0.57)
# 2614
Out of 5,441 analysts
51
Total ratings
Success rate
Average return
Main Sectors:
Top Industries:
19 Stocks
Name Action PT Current % Upside Ratings Updated
VOR Vor Biopharma
Maintains: Neutral
1 1
1.99 -49.75% 4 Jun 27, 2025
FATE Fate Therapeutics
Maintains: Neutral
5 4
0.94 325.53% 2 May 14, 2025
ALLO Allogene Therapeutic...
Maintains: Outperform
12 9
1.03 773.79% 3 May 14, 2025
CARM CARISMA Therapeutics
Downgrades: Neutral
10 1
n/a n/a 3 Dec 12, 2024
INKT MiNK Therapeutics
Maintains: Outperform
80 40
12.23 227.06% 2 Nov 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
77 106
69.11 53.38% 5 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
24 18
10.75 67.44% 2 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
180 180
28.28 536.49% 9 Sep 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
140 120
4.97 2314.49% 3 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
8
1.51 429.8% 1 Jun 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
46 52
55.44 -6.2% 2 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
84
31.9 163.32% 1 Oct 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
200 25
n/a n/a 3 Sep 26, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
6 8
2.75 190.91% 4 Aug 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
21 6
4.91 6.92% 2 Aug 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
5
1 400% 1 Nov 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
9
3.2 181.25% 1 Sep 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
n/a
n/a n/a 2 May 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
6 9
3.08 192.21% 1 Oct 7, 2021